13D/13G Filings - KKR Genetic Disorder L.P.

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
Transaction
Date
Type Company
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev Report View
2025-03-07
6:15 pm
Sale
2025-03-05 13D BridgeBio Pharma, Inc.
BBIO
KKR Genetic Disorder L.P. 19,260,971
10.100%
-6,000,000decrease
(-23.75%)
Filing
History
2024-09-17
6:41 pm
Sale
2024-09-13 13D BridgeBio Pharma, Inc.
BBIO
KKR Genetic Disorder L.P. 25,260,971
13.400%
-5,800,000decrease
(-18.67%)
Filing
History
2021-02-17
5:28 pm
Sale
2020-02-11 13D BridgeBio Pharma, Inc.
BBIO
KKR Genetic Disorder L.P. 31,060,971
20.900%
-3,450,000decrease
(-10.00%)
Filing
History
2020-10-06
4:45 pm
Unchanged
2020-10-05 13D BridgeBio Pharma, Inc.
BBIO
KKR Genetic Disorder L.P. 34,510,971
28.200%
0
(Unchanged)
Filing
History
2020-06-01
5:09 pm
Sale
2020-05-28 13D BridgeBio Pharma, Inc.
BBIO
KKR Genetic Disorder L.P. 34,510,971
28.400%
-2,389,690decrease
(-6.48%)
Filing
History